Pazufloxaxin CAS:127045-41-4

Pazufloxacin is commonly prescribed for the treatment of respiratory tract infections caused by susceptible pathogens such as Streptococcus pneumoniae and Haemophilus influenzae. It is also effective against urinary tract infections, including cystitis and pyelonephritis, caused by Escherichia coli and other uropathogens. In dermatology, pazufloxacin is utilized for skin and soft tissue infections like cellulitis, abscesses, and wound infections. Its ability to penetrate tissues effectively makes it suitable for treating deep-seated infections caused by susceptible bacteria. For intra-abdominal infections such as peritonitis or cholecystitis, pazufloxacin can be administered to target enteric pathogens like E. coli and Klebsiella species. Its broad spectrum of activity and good tissue penetration properties make it a valuable option for combating complex abdominal infections. Adverse effects of pazufloxacin may include gastrointestinal disturbances, central nervous system effects like headache or dizziness, and rare but serious reactions such as tendon damage. Patients should be advised on proper medication use, potential side effects, and the importance of completing the full course of treatment to prevent resistance development. Healthcare providers play a crucial role in prescribing pazufloxacin judiciously and monitoring patients for optimal therapeutic outcomes while minimizing risks.